We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Drugmakers submitting ANDAs for products using transdermal delivery systems are expected to demonstrate that they made “reasonable efforts” to optimize the adhesive characteristics of their patches, the FDA says. Read More
As pharmacy benefit managers’ exclusion lists grow longer, drug developers hoping to avoid exclusion must scramble to demonstrate the clinical superiority and cost-effectiveness of their products, according to a new report. Read More
Clinical research organizations foresee specific technologies redefining trial design, but also posing data integrity risks due to minimal FDA guidance. Read More
The FDA wants clinical researchers to improve their electronic data capture systems to ensure interoperability with electronic health records used by healthcare organizations. Read More
France is tightening restrictions on early-phase clinical trials in the wake of one study that left one patient brain-dead and hospitalized five others. Read More
Drugmakers seeking approval of osteoporosis candidates should bolster their submissions with nonclinical pharmacology studies to determine adverse effects, the FDA advises. Read More